¼¼°èÀÇ Ä«Æä½ÃŸºó(Capecitabine) ½ÃÀå
Capecitabine
»óǰÄÚµå : 1785919
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 220 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ä«Æä½ÃŸºó(Capecitabine) ½ÃÀåÀº 2030³â±îÁö 5¾ï 2,870¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 4¾ï 2,740¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀåÀº 2024-2030³â¿¡ CAGR 3.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 5¾ï 2,870¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ È­ÇÐ ±â¹Ý API´Â CAGR 4.3%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 3,350¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ý¹°ÇÐÀû API ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 3.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 1,640¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ä«Æä½ÃŸºó ½ÃÀåÀº 2024³â¿¡ 1¾ï 1,640¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 660¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.4%¿Í 2.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå : ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Ä«Æä½ÃŸºó ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Ä«Æä½ÃŸºó ¼¼°è ½ÃÀåÀº ¾Ï ¹ßº´·ü Áõ°¡¿Í È¿°úÀûÀÎ È­Çпä¹ý Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ²ÙÁØÈ÷ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. °æ±¸¿ë È­Çпä¹ýÁ¦ÀÎ Ä«Æä½ÃŸºóÀº ´ëÀå¾Ï, À¯¹æ¾Ï, À§¾Ï Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ¾Ï °ü¸® ÇÁ·ÎÅäÄÝÀÇ Áß¿äÇÑ ÄÄÆ÷³ÍÆ®°¡ µÇ°í ÀÖ½À´Ï´Ù. »ýȰ½À°üÀÇ º¯È­, Àα¸ °í·ÉÈ­, À¯ÀüÀû ¼ÒÀÎ µîÀ¸·Î ÀÎÇØ ¾Ï ȯÀÚ´Â Áõ°¡Çϰí ÀÖÀ¸¸ç, È¿°úÀûÀÌ°í ³»¾à¼ºÀÌ ÁÁÀº Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¿ä±¸´Â °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤¸ÆÁֻ纸´Ù °æ±¸¿ë È­Çпä¹ýÀÌ È¯Àڵ鿡°Ô ´õ Æí¸®Çϰí Åë¿øÄ¡·áÀÇ Çʿ伺À» ÁÙÀÏ ¼ö ÀÖ´Ù´Â Á¡µµ Ä«Æä½ÃŸºóÀÇ »ç¿ë È®´ë¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

Á¾¾çÇÐÀÇ ¹ßÀüÀº ¾î¶»°Ô Ä«Æä½ÃŸºóÀÇ º¸±ÞÀ» ÃËÁøÇϰí Àִ°¡?

ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸¿Í ÀÓ»ó½ÃÇè¿¡¼­ º´¿ë¿ä¹ý¿¡¼­ Ä«Æä½ÃŸºóÀÇ È¿°ú¸¦ °ËÅäÇϰí ÀÖ½À´Ï´Ù. Ä«Æä½ÃŸºóÀº Á¾Á¾ ´Ù¸¥ È­Çпä¹ýÁ¦³ª Ç¥ÀûÄ¡·áÁ¦¿Í º´¿ëÇÏ¿© Ä¡·á ¼ºÀûÀ» ³ôÀ̰í ȯÀÚÀÇ »ýÁ¸À²À» Çâ»ó½Ãŵ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý ¾Ï Ä¡·áÀÇ Çõ½Åµµ Ä«Æä½ÃŸºó ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ¾Ï Àü¹®ÀǵéÀº ȯÀÚ °³°³ÀÎÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á ¿ä¹ýÀ» Á¶Á¤Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾à¹°ÀÇ È¿´ÉÀ» Çâ»ó½ÃŰ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇÑ »õ·Î¿î Á¦Çü°ú ¼­¹æÇü Á¦Á¦ÀÇ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ȯÀÚ³ª ÀÇ·áÁø¿¡°Ô ´õ¿í ¸Å·ÂÀûÀÎ ¼±ÅÃÁö°¡ µÇ°í ÀÖ½À´Ï´Ù.

½ÅÈï ÇコÄÉ¾î ½ÃÀå¿¡¼­ ½ÃÀåÀÌ ¼ºÀåÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Ä«Æä½ÃŸºó ½ÃÀåÀº ƯÈ÷ ¾Ï ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä« µî ½ÅÈï ÇコÄÉ¾î ½ÃÀå¿¡¼­ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¢±Ù¼º Çâ»ó, ¾Ï Ä¡·á¿¡ ´ëÇÑ Á¤ºÎ ±¸»ó Áõ°¡, ÀǾàǰ À¯Åë¸Á È®´ë·Î ÀÎÇØ ´õ ¸¹Àº ȯÀÚµéÀÌ Ä«Æä½ÃŸºóÀ» ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ Ä«Æä½ÃŸºóÀÇ Á¦³×¸¯ ÀǾàǰÀÌ Àú·ÅÇÑ °¡°ÝÀ¸·Î Ãâ½ÃµÇ¸é¼­ ÁßÀú¼Òµæ ±¹°¡¿¡¼­µµ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á ½Ã¼³ÀÇ È®´ë¿Í Á¶±â ¹ß°ß ¹× Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Ä«Æä½ÃŸºó ¼ö¿ä´Â Àü ¼¼°è ½ÃÀå¿¡¼­ ¾ÈÁ¤ÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Ä«Æä½ÃŸºó ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡¿Í 1Â÷ Ä¡·á ¿É¼ÇÀ¸·Î È­Çпä¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ Áß½ÉÀÇ Ä¡·á Á¢±Ù ¹æ½ÄÀ¸·ÎÀÇ ÀüȯÀ¸·Î Ä«Æä½ÃŸºó°ú °°Àº °æ±¸¿ë È­Çпä¹ýÁ¦¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, Á¤¸Æ¿ä¹ý¿¡ ºñÇØ Åõ¿©°¡ ¿ëÀÌÇÏ°í »îÀÇ ÁúÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÇöÀç ÁøÇà ÁßÀÎ º´¿ë¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸·Î ÀÎÇØ ¾à¹°ÀÇ Àû¿ë ¹üÀ§°¡ È®´ëµÇ°í ½ÃÀå °¡´É¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇコÄɾî ÅõÀÚ Áõ°¡¿Í ºñ¿ë È¿À²ÀûÀÎ Á¦³×¸¯ Á¦Á¦ÀÇ µµÀÔÀ¸·Î Ä«Æä½ÃŸºóÀº ´Ù¾çÇÑ °èÃþ¿¡¼­ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÇÕ¼º À¯Çü(È­ÇÐ ±â¹Ý API, »ý¹°ÇÐÀû API, °íȰ¼º API(HPAPI)), ÀûÀÀÁõ(À¯¹æ¾Ï, ´ëÀå¾Ï, À§¾Ï, ÃéÀå¾Ï, ±âŸ ÀûÀÀÁõ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Capecitabine Market to Reach US$528.7 Million by 2030

The global market for Capecitabine estimated at US$427.4 Million in the year 2024, is expected to reach US$528.7 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Chemical-based API, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$233.5 Million by the end of the analysis period. Growth in the Biological API segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$116.4 Million While China is Forecast to Grow at 6.8% CAGR

The Capecitabine market in the U.S. is estimated at US$116.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$106.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Capecitabine Market: Key Trends & Drivers Summarized

What Is Fueling the Growth of the Capecitabine Market?

The global capecitabine market is witnessing steady growth, driven by the increasing prevalence of cancer and the rising demand for effective chemotherapy treatments. Capecitabine, an oral chemotherapy drug, is widely used for the treatment of colorectal, breast, and gastric cancers, making it a crucial component of cancer management protocols. With cancer cases on the rise due to lifestyle changes, aging populations, and genetic predispositions, the need for effective and well-tolerated treatment options continues to grow. The preference for oral chemotherapy over intravenous administration has further contributed to the expanding use of capecitabine, as it offers greater convenience for patients and reduces the need for hospital visits.

How Are Advancements in Oncology Boosting Capecitabine Adoption?

The field of oncology is undergoing rapid advancements, with ongoing research and clinical trials exploring the efficacy of capecitabine in combination therapies. Capecitabine is often used in conjunction with other chemotherapy agents or targeted therapies to enhance treatment outcomes and improve patient survival rates. Innovations in personalized medicine and biomarker-driven cancer therapies have also influenced the capecitabine market, as oncologists increasingly tailor treatment regimens based on individual patient profiles. Additionally, new drug formulations and extended-release versions are being developed to improve the drug’s efficacy and minimize side effects, making it a more attractive option for both patients and healthcare providers.

Why Is the Market Growing in Emerging Healthcare Markets?

The capecitabine market is witnessing significant growth in emerging healthcare markets, particularly in Asia-Pacific and Latin America, where cancer incidence rates are rising. Improved access to healthcare, increasing government initiatives for cancer treatment, and the expansion of pharmaceutical distribution networks have made capecitabine more accessible to a larger patient population. Additionally, the growing affordability of generic versions of capecitabine has enabled wider adoption in low- and middle-income countries. With the expansion of cancer care facilities and increased awareness about early detection and treatment, the demand for capecitabine is expected to grow steadily across global markets.

What Factors Are Driving Market Expansion?

The growth in the capecitabine market is driven by several factors. The rising global burden of cancer and the increasing focus on chemotherapy as a primary treatment option have significantly boosted market demand. The shift towards patient-centric treatment approaches has led to a growing preference for oral chemotherapy drugs like capecitabine, which offer ease of administration and improved quality of life compared to intravenous therapies. Regulatory approvals and ongoing research into combination therapies have also expanded the drug’s applicability, enhancing its market potential. Additionally, increasing healthcare investments, coupled with the introduction of cost-effective generic formulations, are making capecitabine more accessible across diverse demographics, contributing to sustained market growth.

SCOPE OF STUDY:

The report analyzes the Capecitabine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Synthesis Type (Chemical-based API, Biological API, Highly Potent API (HPAPI)); Indication (Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â